default author photo

Scott J. Rodig

Harvard University - Dana-Farber Cancer Institute

450 Brookline Avenue

Boston, MA 02215

United States

SCHOLARLY PAPERS

2

DOWNLOADS

176

TOTAL CITATIONS

5

Scholarly Papers (2)

1.

Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

Number of pages: 44 Posted: 13 Sep 2021
Harvard University - Brigham and Women's HospitalHarvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of Virginia, Mayo Clinic, Duke University - Duke Cancer Institute, Rutgers University, New Brunswick - Rutgers Cancer Institute of New Jersey, University of Wisconsin School of Medicine, Cleveland Clinic, Thomas Jefferson University Hospital, Siteman Cancer Center, University of Pittsburgh - Medical Center (UPMC), Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the Italian Republic (Italy) - National Cancer Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Dana-Farber Cancer Institute - Department of Data Science, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Government of the United States of America - National Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Davis - Department of Radiation Oncology and Harvard University - Melanoma Center
Downloads 93 (725,554)
Citation 5

Abstract:

Loading...

2.

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older with Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in Pd-L1 High (≥50%) Patients

Number of pages: 35 Posted: 03 Jan 2025
Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Imperial College London, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Los Angeles (UCLA), Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, MD Anderson Cancer Center - Department of Gastroenterology, Hepatology and Nutrition, affiliation not provided to SSRN, University of Kansas - Cancer Center, University of Kansas - University of Kansas Medical Center, Vanderbilt University, Vanderbilt University - Medical Center, Imperial College London, Harvard University - Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute and University of Oklahoma - Stephenson Cancer Center
Downloads 83 (783,685)

Abstract:

Loading...

Non-Small Cell Lung Cancer, immunotherapy, pembrolizumab, Tumor microenvironment, Tumor immunophenotype, Older adults